Capital Impact Advisors’s Beam Therapeutics BEAM Stock Holding History

Capital Impact Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,229	Closed	-$224K	–	96
2023 Q4	$224K	Buy	+8,229	New	+$204K	0.29%	90
2023 Q3	–	Sell	-12,600	Closed	-$402K	–	117
2023 Q2	$402K	Hold	12,600	–	–	0.44%	110
2023 Q1	$386K	Buy	12,600 +445	+4%	+$17.6K	0.47%	98
2022 Q4	$475K	Buy	12,155 +458	+4%	+$20.5K	0.46%	84
2022 Q3	$554K	Buy	11,697 +2,766	+31%	+$158K	0.55%	65
2022 Q2	$346K	Buy	8,931 +1,732	+24%	+$68.8K	0.32%	139
2022 Q1	$413K	Sell	7,199 -273	-4%	-$17.9K	0.3%	150
2021 Q4	$595K	Buy	+7,472	New	+$640K	0.41%	75
2021 Q1	–	Sell	-25,000	Closed	-$2.04M	–	113
2020 Q4	$2.04M	Buy	+25,000	New	+$1.23M	0.5%	78

Other funds holding BEAM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Capital Impact Advisors's BEAM Position: Q1 2024 in Review

Capital Impact Advisors sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 8,229 shares — an estimated $224K sold.

Capital Impact Advisors first reported a position in BEAM in Q4 2020 and held it in 9 quarters. The position peaked at $2.04M in Q4 2020. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

Capital Impact Advisors reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
Capital Impact Advisors sold 8,229 Beam Therapeutics shares in Q1 2024, an estimated $224K.
Capital Impact Advisors first reported a position in Beam Therapeutics in Q4 2020 and held it in 9 quarters.
Capital Impact Advisors's Beam Therapeutics position peaked at $2.04M in Q4 2020.
221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Capital Impact Advisors's 13F filing for Q1 2024, filed 15 May 2024.